Sun Pharmaceutical Industries Ltd has acquired the rights to trademarks of diabetes drug dapagliflozin under brands Oxra, Oxramet and Oxraduo in India from AstraZeneca AB, Sweden, the parent company of AstraZeneca Pharma India.

Sun Pharma has also taken a patent license to manufacture and commercialize dapagliflozin and dapagliflozin with metformin combination in India from AstraZeneca AB with effect from 28th May, 2021.

Consequently, AstraZeneca India and Sun Pharma have now discontinued the distribution agreement signed in 2016 and have entered into a transition supply agreement with effect from May 28th 2021.

Under the transition supply agreement, AstraZeneca India will supply dapagliflozin and the combination of dapagliflozin with metformin to Sun Pharma until such period of time as mutually agreed between the parties, post which all supplies to Sun Pharma from AstraZeneca India shall cease.